1
|
Heuer L, Wilhelm C, Roy O, Löhlein W, Wolf O, Zschiesche E. Clinical safety and efficacy of a single-dose gentamicin, posaconazole and mometasone furoate otic suspension for treatment of canine otitis externa. Vet Rec 2024; 194:e3955. [PMID: 38462781 DOI: 10.1002/vetr.3955] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2023] [Revised: 01/30/2024] [Accepted: 02/05/2024] [Indexed: 03/12/2024]
Abstract
BACKGROUND A single-dose, in-clinic, veterinary professional-administered treatment for canine otitis externa was developed to improve compliance and canine welfare. METHODS This multicentre, controlled, examiner-masked, randomised field trial was conducted in 316 dogs over 42 days. Dogs were treated once, on day 0, with the investigational product containing gentamicin, posaconazole and mometasone furoate (Mometamax Ultra [MU]) or twice (days 0 and 7) with a control product containing florfenicol, terbinafine and betamethasone acetate (CP). The primary endpoint was a composite otitis index score of 4 or less (of 12) on day 14 and 3 or less (of 12) on day 28. RESULTS On day 28, treatment success was recorded in 128 of 143 MU-treated dogs (89.5%), significantly non-inferior to 116 of 133 (87.2%) CP-treated dogs (Farrington-Manning test, Z = 4.1351, p < 0.0001). For mixed cultures of Staphylococcus pseudintermedius and Malassezia pachydermatis, there was 100% treatment success in MU-treated dogs (n = 33), significantly non-inferior to 90.2% (37 of 41) in CP-treated dogs (Farrington-Manning test, Z = 3.1954, p = 0.0007). LIMITATIONS Efficacy in chronic otitis externa cases was not investigated. Cytology was not used to aid in diagnosis or for identification of secondary pathogens. CONCLUSION This unique combination, single-dose product is safe and effective in dogs with otitis externa. It offers enhanced compliance, canine welfare and quality of life by eliminating the owner burden of treating this painful condition.
Collapse
Affiliation(s)
- Lea Heuer
- MSD Animal Health Innovation, Schwabenheim an der Selz, Germany
| | | | | | | | - Oliver Wolf
- Löhlein & Wolf Vet Research and Consulting, München, Germany
| | - Eva Zschiesche
- MSD Animal Health Innovation, Schwabenheim an der Selz, Germany
| |
Collapse
|
2
|
Raulf MK, Raue K, Rohdich N, Zschiesche E, Raue J, Merhof K, Volk HA, Schnyder M, Morelli S, Traversa D, Roepke RKA, Strube C. Efficacy of Bravecto ® Plus spot-on solution for cats (280 mg/ml fluralaner and 14 mg/ml moxidectin) in the prevention of feline Aelurostrongylus abstrusus infection evaluated in a multi-diagnostic approach. Parasit Vectors 2024; 17:193. [PMID: 38658960 PMCID: PMC11044604 DOI: 10.1186/s13071-024-06270-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2024] [Accepted: 04/03/2024] [Indexed: 04/26/2024] Open
Abstract
BACKGROUND Aelurostrongylus abstrusus is one of the most important respiratory nematodes of felines. Infections may lead to respiratory clinical signs with varying severity or even death, emphasizing the need for preventive treatment of cats with outdoor access to circumvent patent infections. METHODS Therefore, the preventive efficacy of a spot-on formulation of 280 mg/ml fluralaner and 14 mg/ml moxidectin (Bravecto® Plus spot-on solution for cats, MSD) against A. abstrusus was evaluated in a negative controlled, randomized and partially blinded efficacy study with 28 purpose-bred cats in a non-terminal design. In three different treatment regimes, the minimum recommended dose of 40 mg fluralaner and 2.0 mg moxidectin/kg bodyweight (BW) was administered once at 12, 8 or 4 weeks (study group G1, G2 and G3, respectively) prior to experimental infection with 300 third-stage A. abstrusus larvae, while G4 served as placebo-treated control. RESULTS From 30 to 46 days post infection (dpi; SD 114 to 130), faeces were sampled to monitor first-stage larvae (L1) excretion for efficacy determination. Secondary efficacy criteria, including respiratory parameters, serological antibody levels and computed tomography (CT) findings, were assessed once before enrolment (SD -7 to -1) and before infection (SD 75 to 83). After infection, CT evaluation was performed once at 47-50 dpi (SD 131 to 134), and respiratory parameters and antibody levels were regularly assessed twice or once a week, respectively (1 up to 78 dpi, SD 85 up to 162). All animals in the control group excreted L1 by 33-37 dpi and remained positive throughout the study period from 41 to 46 dpi (SD 125 to 130). In the treatment groups, only one animal each of G1 and G2 excreted L1 at two consecutive days, and four cats of G1, two of G2 and three of G3 were positive on single occasions. While the geometric mean (GM) of the maximum number of excreted L1 per 5 g of faeces was 7380.89 in the control group (G4), GMs were significantly lower in the treatment groups with 1.63 in G1, 1.37 in G2 and 0.79 in G3. Thus, based on GMs, the reduction in excreted L1 exceeded 99.9% in all three treatment groups. Based on CT severity scores, all lungs of the animals of the control group showed severe pulmonary changes post infection, whereas lungs of the cats of the treatment groups were either unaltered (4 animals), mildly (11 animals), or moderately altered (5 animals). Moreover, seroconversion was observed in all cats of the control group, but not in those of the treatment groups. CONCLUSIONS The combination of diagnostic methods used in this non-terminal study yielded coherent and reliable results. A single administration of Bravecto® Plus spot-on solution for cats was well tolerated and effective in the prevention of aelurostrongylosis for at least 12 weeks.
Collapse
Affiliation(s)
- Marie-Kristin Raulf
- Institute for Parasitology, Centre for Infection Medicine, University of Veterinary Medicine Hannover, Buenteweg 17, 30559, Hanover, Germany
| | - Katharina Raue
- Institute for Parasitology, Centre for Infection Medicine, University of Veterinary Medicine Hannover, Buenteweg 17, 30559, Hanover, Germany
| | - Nadja Rohdich
- MSD Animal Health Innovation GmbH, Schwabenheim, Germany
| | - Eva Zschiesche
- MSD Animal Health Innovation GmbH, Schwabenheim, Germany
| | - Jonathan Raue
- Department for Small Animal Medicine and Surgery, University of Veterinary Medicine Hannover, 30559, Hannover, Germany
| | - Kristina Merhof
- Department for Small Animal Medicine and Surgery, University of Veterinary Medicine Hannover, 30559, Hannover, Germany
| | - Holger A Volk
- Department for Small Animal Medicine and Surgery, University of Veterinary Medicine Hannover, 30559, Hannover, Germany
| | - Manuela Schnyder
- Institute of Parasitology, Vetsuisse Faculty, University of Zurich, 8057, Zurich, Switzerland
| | - Simone Morelli
- Department of Veterinary Medicine, University of Teramo, Teramo, Italy
| | - Donato Traversa
- Department of Veterinary Medicine, University of Teramo, Teramo, Italy
| | | | - Christina Strube
- Institute for Parasitology, Centre for Infection Medicine, University of Veterinary Medicine Hannover, Buenteweg 17, 30559, Hanover, Germany.
| |
Collapse
|
3
|
Di Cesare A, Morelli S, Rohdich N, Kirkova Z, Capári B, Loehlein W, Wolf O, Zschiesche E, Colombo M, Astuti C, Traversa D. Efficacy of a spot-on formulation containing 280 mg/ml fluralaner and 14 mg/ml moxidectin (Bravecto® Plus) in the prevention of cat aelurostrongylosis under field conditions. Vet Parasitol 2024; 327:110114. [PMID: 38286060 DOI: 10.1016/j.vetpar.2024.110114] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2023] [Revised: 01/09/2024] [Accepted: 01/09/2024] [Indexed: 01/31/2024]
Abstract
Aelurostrongylus abstrusus is the most important respiratory nematode of domestic cats. Effective control options are crucial to protect health and welfare of cats and to reduce the spread of aelurostrongylosis in both enzootic and free regions. The present study evaluated the efficacy of a spot-on formulation containing 280 mg/ml fluralaner and 14 mg/ml moxidectin (Bravecto® Plus, MSD) in the prevention of aelurostrongylosis in cats under field conditions. One hundred and fifty-two cats from Italy, Hungary and Bulgaria, were randomly divided in two groups, one treated with Bravecto® Plus on Study Days (SDs) 0 and 84 (74 cats, IVP Group) and one left untreated (78 cats, control group). Faecal samples were collected from all animals on SDs 42 ± 4, 84, 126 ± 4 and 168 ± 4 and subjected to the Baermann's technique and species-specific PCR for A. abstrusus. Each cat was subjected to a clinical examination on SDs 0, 84 and 168 ± 4 to check health condition and possible adverse events. The results of the faecal analysis were statistically analyzed for treatment group differences in the percentage of cats negative to the Baermann's test and PCR and percentage of reduction of fecal larvae counts as the primary and secondary efficacy criteria, respectively. The percentage of negative cats was higher in the IVP group compared to the control group and the percentage of reduction of fecal larvae counts in the IVP group compared to the control group was 100%. These results show that two administrations of Bravecto Plus® spot-on 12 weeks apart were safe and effective in the prevention of aelurostrongylosis for a period of almost 6 months.
Collapse
Affiliation(s)
- Angela Di Cesare
- Department of Veterinary Medicine, University of Teramo, Località Piano d'Accio, 64100 Teramo, Italy
| | - Simone Morelli
- Department of Veterinary Medicine, University of Teramo, Località Piano d'Accio, 64100 Teramo, Italy
| | - Nadja Rohdich
- MSD Animal Health Innovation GmbH, Zur Propstei, 55270 Schwabenheim, Germany
| | - Zvezdelina Kirkova
- Trakia University, Faculty of Veterinary Medicine, Department of Parasitology, Student Campus, 6000 Stara Zagora, Bulgaria
| | | | | | - Oliver Wolf
- Loehlein & Wolf vet research, Maistrasse 69, 80337 Munich, Germany
| | - Eva Zschiesche
- MSD Animal Health Innovation GmbH, Zur Propstei, 55270 Schwabenheim, Germany
| | - Mariasole Colombo
- Department of Veterinary Medicine, University of Teramo, Località Piano d'Accio, 64100 Teramo, Italy
| | - Chiara Astuti
- Department of Veterinary Medicine, University of Teramo, Località Piano d'Accio, 64100 Teramo, Italy
| | - Donato Traversa
- Department of Veterinary Medicine, University of Teramo, Località Piano d'Accio, 64100 Teramo, Italy.
| |
Collapse
|
4
|
Chiummo R, Zschiesche E, Capári B, Farkas R, Chiquet M, Rapti D, Postoli R, Audry A, Leschnik M. Field efficacy of fluralaner (Bravecto ® chewable tablets) for preventing Babesia canis infection transmitted by Dermacentor reticulatus ticks to dogs. Parasit Vectors 2023; 16:252. [PMID: 37501160 PMCID: PMC10373369 DOI: 10.1186/s13071-023-05820-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2023] [Accepted: 05/26/2023] [Indexed: 07/29/2023] Open
Abstract
BACKGROUND The isoxazoline fluralaner is effective for prevention of Babesia canis transmission from infected Dermacentor reticulatus ticks to dogs for 84 days in a controlled environment. This study was designed to evaluate the effectiveness of fluralaner chewable tablets for sustained prevention of B. canis infection of dogs in endemic areas under natural conditions. METHODS In Europe, privately owned, clinically healthy pet dogs were enrolled and randomized either to receive fluralaner at 25-56 mg/kg (Bravecto® chewable tablets) on days 0 and 84, or to remain untreated during the D. reticulatus season. Blood samples were collected to evaluate B. canis exposure: on days 0 and 21 (exposure before day 0), during the study and at the end of the tick season (dogs suspected of having become infected after day 0). Efficacy was determined by the percentage reduction in B. canis transmission risk based on the difference in B. canis-positive tests in fluralaner-treated dogs compared with untreated dogs. In addition, ticks collected at monthly intervals throughout the study were identified to species level and females tested for B. canis DNA. RESULTS A total of 152 dogs were enrolled in the study, although nine dogs were excluded because they tested positive for B. canis DNA or antibodies within 21 days after enrollment. During the study period, no fluralaner-treated dog became positive for B. canis, resulting in calculated efficacy of 100%. However, babesiosis infection was diagnosed in five untreated control dogs (Fisher's exact test, left-sided, P = 0.0312). Tick analyses revealed that one sample collected in Hungary was infected with B. canis. CONCLUSION Oral administration of Bravecto chewable tablets at the recommended dosage to dogs completely prevented B. canis transmission under field conditions in an endemic area for 12 weeks.
Collapse
Affiliation(s)
- Rafael Chiummo
- MSD Animal Health Innovation GmbH, Zur Propstei, 55270 Schwabenheim, Germany
| | - Eva Zschiesche
- MSD Animal Health Innovation GmbH, Zur Propstei, 55270 Schwabenheim, Germany
| | | | - Róbert Farkas
- Department of Parasitology and Zoology, University of Veterinary Medicine, Budapest, 1078 Hungary
| | - Mathieu Chiquet
- Artemis Animal Health, 7, rue du Clos Rouillé, Champtocé-sur-Loire, France
| | - Dhimitër Rapti
- Faculty of Veterinary Medicine, Agricultural University of Tirana, Tirana, Albania
| | - Rezart Postoli
- Faculty of Veterinary Medicine, Agricultural University of Tirana, Tirana, Albania
| | - Alain Audry
- Clinique Vétérinaire, 2c Route de Grayan, 33780 Soulac sur Mer, France
| | - Michael Leschnik
- University Clinic for Small Animals, Veterinary University Vienna, Vienna, Austria
| |
Collapse
|
5
|
dos Santos KC, Chiummo RM, Heckeroth AR, Zschiesche E, Brandão Guedes PE, Harvey TV, de Jesus AV, da Paixão Sevá A, de Oliveira JTS, dos Santos Freire Z, Krücken J, de Almeida Borges F, von Samson-Himmelstjerna G, Alberto Carlos RS. Efficacy of oral fluralaner (Bravecto) against Tunga penetrans in dogs: A negative control, randomized field study in an endemic community in Brazil. PLoS Negl Trop Dis 2022; 16:e0010251. [PMID: 35286319 PMCID: PMC8947607 DOI: 10.1371/journal.pntd.0010251] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2021] [Revised: 03/24/2022] [Accepted: 02/11/2022] [Indexed: 12/01/2022] Open
Abstract
The sand flea Tunga penetrans is one of the zoonotic agents of tungiasis, a parasitic skin disease of humans and animals. The dog is one of its main reservoirs. This negatively controlled, randomized, double-masked clinical trial evaluated the therapeutic and residual efficacy of fluralaner for treatment of dogs naturally infested with T. penetrans. Sixty-two dogs from an endemically affected community in Brazil were randomly assigned to either receive oral fluralaner (Bravecto chewable tablets) at a dose of 25 to 56 mg fluralaner/kg body weight, or no treatment (31 dogs per group). Dogs were clinically examined using a severity score for acute canine tungiasis (SCADT), parasitological examinations as defined by the Fortaleza classification, and pictures of lesions on days 0 (inclusion and treatment), 7 ± 2, 14 ± 2, 21 ± 2, 28 ± 2, 60 ± 7, 90 ± 7, 120 ± 7 and 150 ± 7. The percentage of parasite-free dogs after treatment was >90% between days 14 and 90 post-treatment with 100% efficacy on study days 21, 28 and 60. Sand flea counts on fluralaner treated dogs were significantly lower (p<0.025) than control dogs on all counts from day 7 to 120. The number of live sand fleas on treated dogs was reduced by > 90% on day 7, > 95% on days 14 and 90, and 100% from day 21 to 60, and with a significant difference between groups from day 7 to 120. From day 7 to day 120, mean SCADT scores were significantly reduced in treated dogs with a mean of 0.10 compared to 1.54 on day 120 in untreated dogs. Therefore, a single oral fluralaner administration is effective for treating and achieving long lasting (> 12 weeks) prevention for tungiasis in dogs. Tungiasis is a dermatological disease that affects humans and animals infested with sand fleas (Tunga spp.), especially in communities exposed to contaminated sandy and dry soil, where living conditions are precarious and access to basic health is limited. These sand fleas penetrate host skin and cause severe acute and chronic injuries that can dramatically compromise the host’s health. Dogs are a primary reservoir and disseminator of these fleas in South America. In this clinical field trial, the efficacy of a single oral dose of fluralaner (Bravecto chewable tablets) was evaluated for treatment and prevention of tungiasis in dogs in an endemic area of Brazil. The treatment was assessed through absence of live sand fleas and resolution of characteristic tungiasis skin lesions. Fluralaner was 100% effective from the third to the eighth week post-treatment, eliminated live sand fleas and protected against new infestations during the study. Therefore, fluralaner proved to be an excellent therapeutic option for treatment and a highly effective control option for canine tungiasis.
Collapse
Affiliation(s)
- Katharine Costa dos Santos
- UESC, State University of Santa Cruz, Department of Agricultural and Environmental Sciences, Postgraduate Program in Animal Science, Ilhéus, Bahia, Brazil
| | | | | | - Eva Zschiesche
- MSD, Animal Health Innovation GmbH, Schwabenheim, Germany
| | - Paula Elisa Brandão Guedes
- UESC, State University of Santa Cruz, Department of Agricultural and Environmental Sciences, Postgraduate Program in Animal Science, Ilhéus, Bahia, Brazil
| | - Tatiani Vitor Harvey
- UESC, State University of Santa Cruz, Department of Agricultural and Environmental Sciences, Postgraduate Program in Animal Science, Ilhéus, Bahia, Brazil
| | - Anderson Vieira de Jesus
- UESC, State University of Santa Cruz, Department of Agricultural and Environmental Sciences, Postgraduate Program in Animal Science, Ilhéus, Bahia, Brazil
| | - Anaiá da Paixão Sevá
- UESC, State University of Santa Cruz, Department of Agricultural and Environmental Sciences, Postgraduate Program in Animal Science, Ilhéus, Bahia, Brazil
| | - Joana Thaisa Santos de Oliveira
- UESC, State University of Santa Cruz, Department of Agricultural and Environmental Sciences, Postgraduate Program in Animal Science, Ilhéus, Bahia, Brazil
| | - Zelina dos Santos Freire
- UFMS, Federal University of Mato Grosso do Sul, Faculty of Veterinary Medicine and Animal Science, Campo Grande, Mato Grosso do Sul, Brazil
| | - Jürgen Krücken
- Freie Universität Berlin, Institute for Parasitology and Tropical Veterinary Medicine, Berlin, Germany
| | - Fernando de Almeida Borges
- UFMS, Federal University of Mato Grosso do Sul, Faculty of Veterinary Medicine and Animal Science, Campo Grande, Mato Grosso do Sul, Brazil
| | - Georg von Samson-Himmelstjerna
- Freie Universität Berlin, Institute for Parasitology and Tropical Veterinary Medicine, Berlin, Germany
- * E-mail: (GvSH); (RSAC)
| | - Renata Santiago Alberto Carlos
- UESC, State University of Santa Cruz, Department of Agricultural and Environmental Sciences, Postgraduate Program in Animal Science, Ilhéus, Bahia, Brazil. CNPq Reseracher - PQ2
- * E-mail: (GvSH); (RSAC)
| |
Collapse
|
6
|
Petersen I, Johannhörster K, Pagot E, Escribano D, Zschiesche E, Temple D, Thomas E. Assessment of fluralaner as a treatment in controlling Dermanyssus gallinae infestation on commercial layer farms and the potential for resulting benefits of improved bird welfare and productivity. Parasit Vectors 2021; 14:181. [PMID: 33789728 PMCID: PMC8011190 DOI: 10.1186/s13071-021-04685-7] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2020] [Accepted: 03/16/2021] [Indexed: 11/17/2022] Open
Abstract
Background Poultry red mite (PRM) (Dermanyssus gallinae) infestations are a cause of anaemia, impaired productivity and stress-related behaviours linked to reduced hen welfare. A study investigated the potential health, welfare and productivity benefits following fluralaner treatment to eliminate PRM from infested hens. Methods A PRM-infested layer house was selected on a free-range farm (5400 hens) and an aviary farm (42,400 hens). Fluralaner (Exzolt®; 0.5 mg/kg body weight) was administered twice, 7 days apart (Weeks 0 and 1), via drinking water. Mite populations were monitored by traps. Cameras recorded nighttime hen behaviours weekly, pre- and post-treatment. On the free-range farm, daytime behaviours were also recorded weekly. For pre- and post-treatment corticosterone assessments, eggs were randomly collected on both farms, and blood samples were collected from 50 randomly selected aviary farm hens. Production parameters were assessed using farm records. Results Throughout the post-treatment period, fluralaner efficacy against PRM was > 99% on both farms. On the aviary and free-range farms, treatment was followed by significant nighttime increases in the proportion of resting hens (P < 0.0001; P = 0.0175, respectively). Significant post-treatment versus pre-treatment nighttime reductions were observed in head shaking (aviary, P < 0.0001; free-range P = 0.0233) and preening (P = 0.0032; P = 0.0018) and on the aviary farm in bouts of body shaking (P = 0.0108), vertical wing shaking (P = 0.0002), head scratching (P = 0.0335), and gentle feather pecking (P < 0.0001). On the free-range farm there were significant daytime reductions in head scratching (P < 0.0001), head shaking (P = 0.0492) and preening (P = 0.0012). Relative to standard production parameters, no differences were detected on the aviary farm, but on the free-range farm the laying rate decline with increasing age was less than expected and the increase in egg weight greater than expected. Post-treatment increases in egg and plasma corticosterone were suggestive of stress factors in addition to mite infestation. Red blood cell counts and haematocrit increased following treatment. Conclusion Fluralaner treatment eliminated mite challenge, leading to improved hen welfare and health, based on reductions in stress-related behaviours and restoration of the anaemia-inducing effects of mite blood feeding. ![]()
Collapse
Affiliation(s)
- Ivo Petersen
- MSD Animal Health Innovation GmbH, Zur Propstei, 55270, Schwabenheim, Germany.
| | | | - Eric Pagot
- Centre Technique Des Productions Animales, Zoopole Dévelopment, 2 rue Jean Rostand, 22440, Ploufragan, France
| | - Damian Escribano
- Interdisciplinary Laboratory of Clinical Analysis (Interlab-UMU), Veterinary School, Campus of Excellence Mare Nostrum, University of Murcia, Campus de Espinardo s/n, 30100, Murcia, Espinardo, Spain.,Animal Production Department, Regional "Campus of Excellence Mare Nostrum", University of Murcia, 30100, Murcia, Espinardo, Spain
| | - Eva Zschiesche
- MSD Animal Health Innovation GmbH, Zur Propstei, 55270, Schwabenheim, Germany
| | - Déborah Temple
- School of Veterinary Medicine, Universitat Autonoma de Barcelona, Bellaterra, Spain
| | - Emmanuel Thomas
- MSD Animal Health Innovation GmbH, Zur Propstei, 55270, Schwabenheim, Germany
| |
Collapse
|
7
|
Raue K, Rohdich N, Hauck D, Zschiesche E, Morelli S, Traversa D, Di Cesare A, Roepke RKA, Strube C. Efficacy of Bravecto ® Plus spot-on solution for cats (280 mg/ml fluralaner and 14 mg/ml moxidectin) for the prevention of aelurostrongylosis in experimentally infected cats. Parasit Vectors 2021; 14:110. [PMID: 33593394 PMCID: PMC7885211 DOI: 10.1186/s13071-021-04610-y] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2020] [Accepted: 01/23/2021] [Indexed: 02/06/2023] Open
Abstract
Background The feline lungworm Aelurostrongylus abstrusus affects the lower respiratory tract in cats worldwide. As infections may lead to chronic respiratory changes or even death, preventive treatment in cats with outdoor access is warranted. Methods The preventive efficacy of a spot-on solution (Bravecto® Plus spot-on solution for cats, MSD) against cat aelurostrongylosis was evaluated using three different preventive treatment regimes in a negative controlled, randomized and partially blinded laboratory efficacy study with 31 purposed-bred cats. The minimum recommended dose of 2.0 mg moxidectin + 40 mg fluralaner/kg bodyweight was applied once 12 (Group [G]1), 8 (G2) or 4 (G3) weeks before experimental infection with 300 third-stage larvae (L3) of A. abstrusus. Another group served as untreated control (G4). Individual faecal samples were analysed as of day 30 post infection (pi) to monitor larvae excretion. Necropsy was performed at days 47–50 pi. The lungs were examined macroscopically for pathological findings and (pre-)adult worms were counted to assess preventive efficacy. Results Beginning at day 32–40 pi, all cats of the control group were constantly shedding larvae of A. abstrusus, whereas only one animal of G1 excreted larvae at several consecutive days. In addition, two cats of G1 and G3 and three of G2 were positive on a single occasion. The geometric mean (GM) of the maximum number of excreted larvae was 7574.29 in the control group compared to 1.10 (G1), 1.19 (G2) and 0.53 (G3), resulting in a GM reduction of > 99.9% in all treatment groups. All lungs of the control animals showed severe or very severe alterations at necropsy, while in 94.44% of the treated cats lung pathology was rated as absent or mild. The GM number of (pre-)adult A. abstrusus retrieved from the lungs was 26.57 in the control group, 0.09 in G1 and 0.00 in G2 and G3. Thus, GM worm count reduction was 99.66% in G1 and 100% in G2 and G3. Conclusions A single application of Bravecto® Plus spot-on solution at a dose of 2.0 mg moxidectin + 40 mg fluralaner/kg bodyweight reliably prevents cat aelurostrongylosis for at least 12 weeks.![]()
Collapse
Affiliation(s)
- Katharina Raue
- Institute for Parasitology, Centre for Infection Medicine, University of Veterinary Medicine Hannover, Hanover, Germany
| | - Nadja Rohdich
- MSD Animal Health Innovation GmbH, Schwabenheim, Germany
| | - Daniela Hauck
- Institute for Parasitology, Centre for Infection Medicine, University of Veterinary Medicine Hannover, Hanover, Germany
| | - Eva Zschiesche
- MSD Animal Health Innovation GmbH, Schwabenheim, Germany
| | - Simone Morelli
- Faculty of Veterinary Medicine, University of Teramo, Teramo, Italy
| | - Donato Traversa
- Faculty of Veterinary Medicine, University of Teramo, Teramo, Italy
| | - Angela Di Cesare
- Faculty of Veterinary Medicine, University of Teramo, Teramo, Italy
| | | | - Christina Strube
- Institute for Parasitology, Centre for Infection Medicine, University of Veterinary Medicine Hannover, Hanover, Germany.
| |
Collapse
|
8
|
Chiummo R, Petersen I, Plehn C, Zschiesche E, Roepke R, Thomas E. Efficacy of orally and topically administered fluralaner (Bravecto ®) for treatment of client-owned dogs with sarcoptic mange under field conditions. Parasit Vectors 2020; 13:524. [PMID: 33069261 PMCID: PMC7568370 DOI: 10.1186/s13071-020-04395-6] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2020] [Accepted: 10/07/2020] [Indexed: 12/30/2022] Open
Abstract
Background Successful canine sarcoptic mange treatment requires immediate efficacy to eliminate active mites, and sustained activity to prevent re-infestation from in-contact animals and fomites. With extended acaricidal activity, fluralaner has been shown to be effective for treating this disease. To confirm this potential under field conditions, two fluralaner formulations were administered to mite-infested, client-owned dogs. Methods Households qualified for inclusion if they had at least one dog positive for Sarcoptes scabiei mites, confirmed by skin scraping, and at least one dog with clinical signs evocative of sarcoptic mange. Households were allocated to groups of dogs to receive a single treatment with either oral (Bravecto® chewable tablets, MSD Animal Health) or topical (Bravecto® Spot-on, MSD Animal Health), fluralaner at a dose of ≥ 25 mg/kg (range 25–56 mg/kg) on Day 0, or two treatments with oral sarolaner (Simparica® tablets, Zoetis) (Days 0 and 28) at ≥ 2 mg/kg (2–4 mg/kg). All dogs in each household were treated with the same product. On the enrolment day and subsequently on Days 28, 56 and 84, deep skin scrapings were taken from at least five different body areas judged to be most likely to have active mite infestation. At each visit, the dog’s mange-associated skin lesions were recorded, and pruritus level was assessed. Results There were 98 participating households and 135 dogs enrolled across Albania, France, Italy and Portugal. On Day 28, more than 90% of dogs in each group were negative for mites. On Days 56 and 84, all study dogs were free of mites and most dermatological signs of sarcoptic mange had resolved. There were no treatment-related adverse events in any group. Conclusions A single treatment of client-owned, sarcoptic mange-affected dogs with either fluralaner chewable tablets or fluralaner spot-on formulation proved a safe and effective treatment of infestations with S. scabiei var. canis, maintained through 84 days (12 weeks) after treatment.![]()
Collapse
Affiliation(s)
- Rafael Chiummo
- MSD Animal Health Innovation GmbH, Schwabenheim, Germany.
| | - Ivo Petersen
- MSD Animal Health Innovation GmbH, Schwabenheim, Germany
| | - Claudia Plehn
- MSD Animal Health Innovation GmbH, Schwabenheim, Germany
| | - Eva Zschiesche
- MSD Animal Health Innovation GmbH, Schwabenheim, Germany
| | - Rainer Roepke
- MSD Animal Health Innovation GmbH, Schwabenheim, Germany
| | | |
Collapse
|
9
|
Petersen I, Chiummo R, Zschiesche E, Karas-Tecza J, Rapti D, Roepke R, Thomas E. A European field assessment of the efficacy of fluralaner (Bravecto ®) chewable and spot-on formulations for treatment of dogs with generalized demodicosis. Parasit Vectors 2020; 13:304. [PMID: 32527282 PMCID: PMC7291464 DOI: 10.1186/s13071-020-04159-2] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2019] [Accepted: 05/30/2020] [Indexed: 12/05/2022] Open
Abstract
Background Recent reports indicate that the isoxazoline compounds have the potential to provide safe and effective treatment of canine generalized demodicosis, a condition that has been traditionally difficult to cure. Controlled field studies are needed to confirm this potential. A study was therefore initiated to investigate the efficacy of a single oral or spot-on treatment with fluralaner, an isoxazoline, compared with multiple topical treatments with imidacloprid-moxidectin, in dogs naturally affected by generalized demodicosis. Methods Veterinary clinics in 5 European countries enrolled 134 dogs diagnosed with generalized demodicosis. Dogs were randomized to treatment with either fluralaner chewables, fluralaner spot-on, or topical imidacloprid-moxidectin in a 2:2:1 ratio. Both fluralaner formulations were administered once, at the approved dose rate, on Day 0. Imidacloprid-moxidectin was administered per label on Day 0, and every 4 weeks, more frequently if necessary. At each visit (Days 0, 28, 56, 84), dogs were monitored for demodectic mites using deep skin scrapings and observed for health and for severity of skin lesions. Treatment was considered efficacious if more than 90% of the dogs were free of live mites at both Days 56 and 84. Results Of 124 dogs completing the study, 57 were diagnosed with juvenile-onset demodicosis and 67 with the adult-onset form. A single treatment with oral or spot-on fluralaner was efficacious, each eliminating mites from at least 98.0% of treated dogs on Days 56 and 84. Against juvenile-onset demodicosis, efficacy of the oral and spot-on formulations was 96.0% and 100%, respectively, and against adult-onset demodicosis 100% and 96.7%. Multiple administrations of imidacloprid-moxidectin were not efficacious, eliminating mites from 87.5% of dogs (92.0% with juvenile-onset demodicosis cured; 81.8% with adult-onset demodicosis). All groups showed a marked reduction in skin lesions by Day 28, with continuing clinical improvement at each subsequent visit through Day 84. There were no treatment-related adverse events. Conclusions A single administration of fluralaner chewables or fluralaner spot-on is highly effective against with juvenile-onset and adult-onset forms of generalized canine demodicosis. Topically applied imidacloprid-moxidectin at weekly to monthly intervals over the 84-day study did not achieve the proportion of mite-free dogs required to demonstrate efficacy. ![]()
Collapse
Affiliation(s)
- Ivo Petersen
- MSD Animal Health Innovation GmbH, Zur Propstei, 55270, Schwabenheim, Germany.
| | - Rafael Chiummo
- MSD Animal Health Innovation GmbH, Zur Propstei, 55270, Schwabenheim, Germany
| | - Eva Zschiesche
- MSD Animal Health Innovation GmbH, Zur Propstei, 55270, Schwabenheim, Germany
| | | | - Dhimiter Rapti
- Faculty of Veterinary Medicine, Agriculture University of Tirana, Tirana, Albania
| | - Rainer Roepke
- MSD Animal Health Innovation GmbH, Zur Propstei, 55270, Schwabenheim, Germany
| | - Emmanuel Thomas
- MSD Animal Health Innovation GmbH, Zur Propstei, 55270, Schwabenheim, Germany
| |
Collapse
|
10
|
Ngoh M, Wrzesinski C, Yang Y, Zschiesche E, Madsen T, Stephenson C, Newman L, Deetz L. Evaluation of the Presence and Level of Enramycin in Broiler Tissues Following In-Feed Administration at Therapeutic Dose. J APPL POULTRY RES 2018. [DOI: 10.3382/japr/pfy031] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
11
|
Rohdich N, Zschiesche E, Wolf O, Loehlein W, Kirkova Z, Iliev P, Rapti D, Postoli R, Capári B, Farkas R, Roepke RKA. A randomized, blinded, controlled, multi-centered field study assessing the treatment of gastrointestinal nematode infections in cats with fluralaner plus moxidectin spot-on solution (Bravecto® Plus). Parasit Vectors 2018; 11:589. [PMID: 30449275 PMCID: PMC6240952 DOI: 10.1186/s13071-018-3169-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2018] [Accepted: 10/25/2018] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND A spot-on formulation containing fluralaner (280 mg/ml) plus moxidectin (14 mg/ml) (Bravecto® Plus) was developed for the treatment of nematode infections as well as providing 12 weeks of protection against insect and acarine parasites in cats. The effectiveness and safety of this product against feline gastrointestinal nematodes was assessed in naturally-infested, client-owned cats under field conditions in Albania, Bulgaria, Germany and Hungary. METHODS To be eligible for enrollment in this investigator-blinded study cats had to be at least 10 weeks-old, weigh at least 1.2 kg, be clinically healthy, and have a faecal sample testing positive for nematodes no more than eight days prior to treatment. Cats were stratified into blocks of three in order of presentation at each center and randomly allocated in a 2:1 ratio to be treated topically on Day 0 with fluralaner plus moxidectin (minimum dose rates 40 mg/kg and 2 mg/kg, respectively) or emodepside plus praziquantel (minimum dose rates 3 mg/kg and 12 mg/kg, respectively) (Profender®). Faecal samples were collected from cats prior to treatment and 14 ± 4 days later. RESULTS There were 182 cats randomized to the fluralaner plus moxidectin group, and 91 to the emodepside plus praziquantel group. Prior to treatment the most commonly identified nematode egg was Toxocara cati, found in 79.1 and 82.4% of cats in the fluralaner plus moxidectin and emodepside plus praziquantel groups, respectively. Eggs of Toxascaris leonina were found in 8.2 and 6.6% of cats; of hookworms in 30.8 and 24.2%; and of Capillaria spp. in 7.1 and 4.3%, respectively. After treatment, faecal samples from 98.3% of fluralaner plus moxidectin treated and 96.6% of emodepside plus praziquantel-treated cats were free of nematode ova. Geometric mean faecal egg count reductions for T. cati, the only eggs found in post-treatment faecal samples, were 99.97% and 99.93%, respectively. Treatment with fluralaner plus moxidectin was non-inferior to emodepside plus praziquantel. Both products were safe and well tolerated by cats treated under field conditions. CONCLUSIONS This field study confirms that, in addition to 12-week extended duration flea and tick control, fluralaner plus moxidectin provides broad spectrum treatment of nematodes in cats.
Collapse
Affiliation(s)
- Nadja Rohdich
- MSD Animal Health Innovation GmbH, Zur Propstei, 55270 Schwabenheim, Germany
| | - Eva Zschiesche
- MSD Animal Health Innovation GmbH, Zur Propstei, 55270 Schwabenheim, Germany
| | - Oliver Wolf
- Loehlein & Wolf Vet Research, Maistrasse 69, 80337 Munich, Germany
| | | | - Zvezdelina Kirkova
- Department of Parasitology, Trakia University, Faculty of Veterinary Medicine, Student Campus, 6000 Stara Zagora, Bulgaria
| | - Petar Iliev
- Department of Parasitology, Trakia University, Faculty of Veterinary Medicine, Student Campus, 6000 Stara Zagora, Bulgaria
| | - Dhimitër Rapti
- Klinika Veterinare Xhimi, Bulevardi Bajram Curri Nr 2, Tirana, Albania
| | - Rezart Postoli
- Faculty of Veterinary Medicine, Agricultural University, Kodër Kamëz, Tirana, Albania
| | | | - Róbert Farkas
- Department of Parasitology and Zoology, Faculty of Veterinary Science, Szent István University, István u. 2, 1078 Budapest VII, Hungary
| | - Rainer K. A. Roepke
- MSD Animal Health Innovation GmbH, Zur Propstei, 55270 Schwabenheim, Germany
| |
Collapse
|
12
|
Rohdich N, Zschiesche E, Wolf O, Loehlein W, Pobel T, Gil MJ, Roepke RKA. Field effectiveness and safety of fluralaner plus moxidectin (Bravecto® Plus) against ticks and fleas: a European randomized, blinded, multicenter field study in naturally-infested client-owned cats. Parasit Vectors 2018; 11:598. [PMID: 30454052 PMCID: PMC6240940 DOI: 10.1186/s13071-018-3175-z] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2018] [Accepted: 10/28/2018] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND A spot-on formulation containing fluralaner (280 mg/ml) plus moxidectin (14 mg/ml) (Bravecto® Plus) has been developed to provide broad spectrum parasite protection for cats. The effectiveness and safety of this product against ticks and fleas was assessed in a randomized, controlled, 12-week study in client-owned cats in Germany and Spain. METHODS Eligible households containing at least one cat with at least two fleas and/or two ticks were allocated randomly in a 2:1 ratio to a single treatment with fluralaner plus moxidectin on Day 0, or three 4-weekly treatments with fipronil (Frontline®). Veterinary staff, masked to treatment, completed tick and flea counts on each cat at 14 ± 2 (2 weeks), 28 ± 2 (4 weeks), 56 ± 2 (8 weeks) and 84 ± 2 days (12 weeks) after the initial treatment. RESULTS In total, 707 cats (257 with ticks) from 332 households (236 with fleas) were included. Ixodes ricinus (78%) and Rhipicephalus sanguineus complex (18%) ticks were the most commonly identified. Tick and flea counts were lower in the fluralaner plus moxidectin group than in the fipronil group throughout the study and the efficacy of fluralaner plus moxidectin exceeded 97 and 98%, respectively. At 12 weeks, 94.1 and 93.3% of cats from the fluralaner plus moxidectin and 92.2 and 60.3% of cats from the fipronil group were free of ticks and fleas, respectively. Fluralaner plus moxidectin was non-inferior to fipronil (P < 0.0001) at all assessments and superior to fipronil at 2 and 8 weeks for the proportion of cats free of ticks (P < 0.0001). Fluralaner plus moxidectin was superior to fipronil for the proportion of both households and cats free of fleas (P < 0.0001). Both products were safe and well tolerated. CONCLUSIONS A single application of fluralaner plus moxidectin spot-on was well tolerated by cats and highly effective for 12 weeks against ticks and fleas. Fluralaner plus moxidectin was non-inferior to fipronil for the proportion of ectoparasite-free and consistently superior to fipronil in controlling fleas.
Collapse
Affiliation(s)
- Nadja Rohdich
- MSD Animal Health Innovation GmbH, Zur Propstei, 55270 Schwabenheim, Germany
| | - Eva Zschiesche
- MSD Animal Health Innovation GmbH, Zur Propstei, 55270 Schwabenheim, Germany
| | - Oliver Wolf
- Loehlein & Wolf Vet Research, Maistrasse 69, 80337 Munich, Germany
| | | | - Thierry Pobel
- TPC Biomed, C/Los Betetas 12-4°D, 42002 Soria, Spain
| | | | - Rainer K. A. Roepke
- MSD Animal Health Innovation GmbH, Zur Propstei, 55270 Schwabenheim, Germany
| |
Collapse
|
13
|
Brauneis MD, Zoller H, Williams H, Zschiesche E, Heckeroth AR. The acaricidal speed of kill of orally administered fluralaner against poultry red mites (Dermanyssus gallinae) on laying hens and its impact on mite reproduction. Parasit Vectors 2017; 10:594. [PMID: 29197422 PMCID: PMC5712167 DOI: 10.1186/s13071-017-2534-5] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2017] [Accepted: 11/13/2017] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Dermanyssus gallinae, the poultry red mite, is a growing threat to chickens in poultry farms. This nocturnal hematophagous ectoparasite has a rapid rate of proliferation with a negative impact on the birds' health, welfare and productivity resulting in severe economic consequences for poultry farmers. A study was performed with fluralaner, a novel systemic ectoparasiticide, to evaluate its effect on mite vitality and reproduction after oral administration to laying hens. METHODS Sixteen healthy hens were randomly allocated to two study groups (n = 8). One group was orally treated with fluralaner by gavage at a dose of 0.5 mg/kg bodyweight twice 7 days apart. The negative control group received no treatment. Hens in each group were repeatedly infested with approximately 200 unfed adult D. gallinae at 1, 5, 8, 12, 15, 19, 22 and 26 days after the initial administration. After infestation and feeding for 2.5 h, 25 engorged mites per hen were collected and incubated in tubes. Mites were assessed for vitality (dead/live) at 4, 8, 12, and 24 h after each infestation. Tubes containing eggs and/or living mites were incubated another 8 days for assessment of mite reproductive capacity. RESULTS Fluralaner demonstrated a fast speed of kill in mites within 4 h post-infestation for 12 days after treatment initiation. An efficacy (mite mortality) of 98.7-100% was achieved. At 15 days after treatment initiation, 100% efficacy was achieved within 24 h post-infestation, and no mite oviposition occurred during this period. Nineteen days after treatment initiation, the mites' ability to generate nymphs was reduced by 90.8%, which decreased to < 24.1% at later infestations. CONCLUSIONS Fluralaner administered orally to hens twice, 7 days apart, provides efficacy against experimental poultry red mite infestation for at least 2 weeks. The demonstrated rapid speed of kill results in substantial depletion of the mites' oviposition and suggests that fluralaner can be an effective tool in the control of D. gallinae, one of the most urgent problems in poultry farms.
Collapse
Affiliation(s)
- Maria D Brauneis
- MSD Animal Health Innovation GmbH, Research Antiparasitics, Zur Propstei, 55270, Schwabenheim, Germany
| | - Hartmut Zoller
- MSD Animal Health Innovation GmbH, Research Antiparasitics, Zur Propstei, 55270, Schwabenheim, Germany
| | - Heike Williams
- MSD Animal Health Innovation GmbH, Research Antiparasitics, Zur Propstei, 55270, Schwabenheim, Germany.
| | - Eva Zschiesche
- MSD Animal Health Innovation GmbH, Research Antiparasitics, Zur Propstei, 55270, Schwabenheim, Germany
| | - Anja R Heckeroth
- MSD Animal Health Innovation GmbH, Research Antiparasitics, Zur Propstei, 55270, Schwabenheim, Germany
| |
Collapse
|
14
|
Thomas E, Chiquet M, Sander B, Zschiesche E, Flochlay AS. Field efficacy and safety of fluralaner solution for administration in drinking water for the treatment of poultry red mite (Dermanyssus gallinae) infestations in commercial flocks in Europe. Parasit Vectors 2017; 10:457. [PMID: 28992814 PMCID: PMC5632831 DOI: 10.1186/s13071-017-2390-3] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2017] [Accepted: 09/18/2017] [Indexed: 11/18/2022] Open
Abstract
Background Welfare concerns, production losses caused by Dermanyssus gallinae, the poultry red mite (PRM), and widespread mite resistance to environmentally applied acaricides continue to drive an urgent need for new and effective control measures. Fluralaner is a novel systemic acaricide developed to address that need. A series of field studies was initiated to investigate the safety and efficacy of a fluralaner solution (10 mg/ml) administered in drinking water at a dose rate of 0.5 mg/kg on two occasions with a 7-day interval, for treatment of natural PRM infestations in chickens. Methods Blinded, negative-controlled studies were completed in Europe across eight layer, two breeder, and two replacement chicken farms. At each farm, two similar flocks were housed in similar PRM-infested units (either rooms within a building, or separate buildings) varying from 550 to 100,000 birds per unit. One unit at each farm was allocated to fluralaner treatment, administered in drinking water on Days 0 and 7. One unit remained untreated. Mite traps were placed throughout each unit on Days -1, 0 or 1, 3, 6, 9, and 13 or 14, then at weekly or two-weekly intervals, retrieved after 24 h and processed for mite counts. Efficacy at each farm was assessed by mean PRM count reductions from traps in treated units compared with those from control units. Production parameters and safety were also monitored. Results Efficacy was 95.3 to 99.8% on Day 3 and 97.8 to 100% on Day 9, thereafter remaining above 90% for 56 to 238 days after treatment initiation. Post-treatment improvement in egg-laying rate was greater by 0.9 to 12.6% in the treated group at 9 of the 10 layer or breeder farms. There were no treatment-related adverse events. Conclusion Fluralaner administered at 0.5 mg/kg via drinking water twice, 7 days apart, was well tolerated and highly efficacious against the PRM in naturally infested chickens representing a range of production types and management systems. The results indicate that this novel treatment has potential to be the cornerstone of an integrated approach to reducing or eliminating the welfare and productivity costs of this increasingly threatening pest.
Collapse
Affiliation(s)
- Emmanuel Thomas
- MSD Animal Health Innovation GmbH, Zur Propstei 55270, Schwabenheim, Germany.
| | - Mathieu Chiquet
- MSD Animal Health Innovation SAS, 7 rue Olivier de Serres, CS 67131, 49071, Angers Technopole, Beaucouzé, France
| | - Björn Sander
- MSD Animal Health Innovation GmbH, Zur Propstei 55270, Schwabenheim, Germany
| | - Eva Zschiesche
- MSD Animal Health Innovation GmbH, Zur Propstei 55270, Schwabenheim, Germany
| | | |
Collapse
|
15
|
Kohler-Aanesen H, Saari S, Armstrong R, Péré K, Taenzler J, Zschiesche E, Heckeroth AR. Efficacy of fluralaner (Bravecto™ chewable tablets) for the treatment of naturally acquired Linognathus setosus infestations on dogs. Parasit Vectors 2017; 10:426. [PMID: 28923117 PMCID: PMC5604360 DOI: 10.1186/s13071-017-2344-9] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2017] [Accepted: 08/23/2017] [Indexed: 11/29/2022] Open
Abstract
Background The clinical efficacy of fluralaner chewable tablets (Bravecto™, MSD Animal Health) against naturally acquired Linognathus setosus infestations on dogs was evaluated compared with permethrin (Exspot®, MSD Animal Health) treatment. Methods Privately-owned dogs naturally infested with L. setosus from 21 different households were randomly allocated to two treatment groups. Fourteen dogs were treated once orally with fluralaner and ten dogs were treated once topically with permethrin, at the recommended label dose. Live L. setosus on all dogs were counted before treatment and 1, 7, 28 (both groups) and 84 (fluralaner group) days post-treatment according to a coat parting technique at pre-specified locations and lice species were confirmed microscopically. At the same time points, a veterinary dermatology severity score and an owner’s perceived pruritus score were recorded. Results Percentage reduction in geometric mean L. setosus counts, comparing post- with pre-treatment counts within each group, were 85.7% (day 1), 96.8% (day 7) and 100% (days 28 and 84) for the fluralaner (two-sided two-sample t-test, P ≤ 0.0088 for days 1–84) and 67.5% (day 1), 90.3% (day 7) 99.1% (day 28) for the permethrin group (two-sided two-sample t-test, P ≤ 0.0014 for days 7–28). No lice were seen on fluralaner-treated dogs 28 and 84 days post-treatment. In contrast, two permethrin-treated dogs were re-treated at 7 and 28 days after initial treatment because of observed lice. Owner’s perceived pruritus scores were reduced compared to pre-treatment levels by 23.8% (day 1), 31.1% (day 7), 70.4% (day 28) and 99.5% (day 84) after fluralaner treatment and 21.3% (day 1), 45.8% (day 7), and 78.1% (day 28) after permethrin treatment. Dermatological signs were improved compared to pre-treatment levels in both treatment groups. Conclusions Single oral fluralaner treatment eliminated natural L. setosus infestation on dogs within 28 days and led to complete dermatological recovery that was maintained until the study end on day 84. Single topical permethrin treatment reduced the number of L. setosus by 99.1% at day 28 although two animals required unscheduled re-treatment.
Collapse
Affiliation(s)
| | - Seppo Saari
- MSD Animal Health, Keilaranta 3, 02150, Espoo, Finland
| | - Rob Armstrong
- Merck Animal Health, 2 Giralda Farms, Madison, NJ, 07940-1026, USA
| | - Karine Péré
- MSD Animal Health Innovation SAS, 7, rue Olivier de Serres, Angers Technopole CS67131, 49071, Beaucouzé, France
| | - Janina Taenzler
- MSD Animal Health Innovation GmbH, Research Antiparasitics, Zur Propstei, 55270, Schwabenheim, Germany.
| | - Eva Zschiesche
- MSD Animal Health Innovation GmbH, Research Antiparasitics, Zur Propstei, 55270, Schwabenheim, Germany
| | - Anja R Heckeroth
- MSD Animal Health Innovation GmbH, Research Antiparasitics, Zur Propstei, 55270, Schwabenheim, Germany
| |
Collapse
|
16
|
Taenzler J, Gale B, Zschiesche E, Roepke RKA, Heckeroth AR. The effect of water and shampooing on the efficacy of fluralaner spot-on solution against Ixodes ricinus and Ctenocephalides felis infestations in dogs. Parasit Vectors 2016; 9:233. [PMID: 27241021 PMCID: PMC4886437 DOI: 10.1186/s13071-016-1367-y] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2015] [Accepted: 02/06/2016] [Indexed: 11/28/2022] Open
Abstract
Background Fluralaner spot-on solution provides immediate and persistent efficacy against tick and flea infestations in dogs and cats for 12-weeks following topical administration. The active ingredient fluralaner is distributed systemically following transdermal absorption. Therefore, this study tested the hypothesis whether water-immersion or shampooing of dogs following administration of fluralaner spot-on solution has an impact on subsequent tick and flea efficacy. Methods Thirty-two Beagle dogs were allocated to four study groups of 8 dogs each. On day 0, dogs in the 2 treatment groups received topical administration of fluralaner (Bravecto™ spot-on solution) according to label instructions. Dogs in the 2 corresponding control groups remained untreated. On days 3, 21, 49, and 77 dogs in one treatment group and control group were water-immersed for 2–5 min, while dogs in the other treatment group and control group were shampooed 6–8 min with a commercial foaming micro-emulsion, unscented product. On days 4, 28, 56, and 84 all dogs were co-infested with 50 ± 2 female and 10 ± 2 male Ixodes ricinus and 100 ± 4 Ctenocephalides felis, with tick and flea removal and counts 48 ± 2 h post-infestation. Efficacy against ticks and fleas was calculated for each assessment time point. Results No treatment-related adverse event was observed in any of the 16 dogs treated with fluralaner spot-on solution during the study. Efficacy against ticks at each assessment time point was between 99.7 and 100 % in the water-immersed group and between 99.2 and 100 % in the shampooed group. Efficacy against fleas was 100 % at each assessment time point as well in the water-immersed as the shampooed group. Tick and flea reduction in both treatment groups was significant at all assessment time points (p < 0.0001). Conclusions Neither water-immersion nor shampooing after single topical administration of fluralaner spot-on solution had an impact on the excellent tick and flea efficacy over the 12-week recommended re-treatment interval.
Collapse
Affiliation(s)
- Janina Taenzler
- MSD Animal Health Innovation GmbH, Zur Propstei, 55270, Schwabenheim, Germany.
| | - Boyd Gale
- Charles River Laboratories Preclinical Services Ireland Ltd, Glenamoy, Co. Mayo, Ireland
| | - Eva Zschiesche
- MSD Animal Health Innovation GmbH, Zur Propstei, 55270, Schwabenheim, Germany
| | - Rainer K A Roepke
- MSD Animal Health Innovation GmbH, Zur Propstei, 55270, Schwabenheim, Germany
| | - Anja R Heckeroth
- MSD Animal Health Innovation GmbH, Zur Propstei, 55270, Schwabenheim, Germany
| |
Collapse
|
17
|
Taenzler J, Liebenberg J, Mienie M, Everett WR, Young DR, Vihtelic TS, Sun F, Zschiesche E, Roepke RKA, Heckeroth AR. Efficacy of fluralaner spot-on solution against induced infestations with Rhipicephalus sanguineus on dogs. Parasit Vectors 2016; 9:276. [PMID: 27241176 PMCID: PMC4886405 DOI: 10.1186/s13071-016-1523-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2016] [Accepted: 04/20/2016] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND The efficacy of fluralaner spot-on solution administered once topically against induced infestations with Rhipicephalus sanguineus was evaluated in dogs over a 12-week post-treatment period. METHODS Six negative-controlled studies were conducted, involving a total of 112 adult dogs (57 mixed breed, 47 Beagles, eight Labradors). In each study, dogs were randomized to two groups of eight to ten dogs each. On day 0, dogs in each treated group were topically administered fluralaner spot-on solution once at a dose of 25 mg/kg body weight, while dogs in each control group were not treated. Two days before treatment, and on days 28, 56 and 84 after treatment, all dogs were infested with approximately 50 unfed, adult Rh. sanguineus ticks (sex ratio 1:1). Ticks were removed and counted on days 2, 30 (4 weeks), 58 (8 weeks), and 86 (12 weeks) after treatment to assess efficacy. RESULTS Efficacy against ticks 2 days after treatment was 91.1 % (study 1), 98.4 % (study 2), 100 % (study 3), 97.6 % (study 4), 99.6 % (study 5), and 99.8 % (study 6). At all other assessment time points, tick efficacy was 95.4-100 %. Tick reduction in all treatment groups was significant at all assessment time points (P < 0.0001). CONCLUSIONS A single topical administration of fluralaner spot-on solution provides a high level of therapeutic and persistent efficacy against Rh. sanguineus ticks over the subsequent 12 weeks.
Collapse
Affiliation(s)
- Janina Taenzler
- MSD Animal Health Innovation GmbH, Zur Propstei, 55270, Schwabenheim, Germany.
| | - Julian Liebenberg
- ClinVet International, Uitsigweg, Bainsvlei, 9338, Bloemfontein, Free State, South Africa
| | - Machiel Mienie
- MSD Animal Health Malelane Research Unit, PO Box 124, Malalane, 1320, Republic of South Africa
| | | | - David R Young
- Young Veterinary Research Services, 7243 East Avenue, Turlock, CA, 95380, USA
| | | | - Fangshi Sun
- Merck Animal Health, 2 Giralda Farms, Madison, NJ, 07940-1026, USA
| | - Eva Zschiesche
- MSD Animal Health Innovation GmbH, Zur Propstei, 55270, Schwabenheim, Germany
| | - Rainer K A Roepke
- MSD Animal Health Innovation GmbH, Zur Propstei, 55270, Schwabenheim, Germany
| | - Anja R Heckeroth
- MSD Animal Health Innovation GmbH, Zur Propstei, 55270, Schwabenheim, Germany
| |
Collapse
|
18
|
Williams H, Zoller H, Roepke RKA, Zschiesche E, Heckeroth AR. Fluralaner activity against life stages of ticks using Rhipicephalus sanguineus and Ornithodoros moubata IN in vitro contact and feeding assays. Parasit Vectors 2015; 8:90. [PMID: 25888750 PMCID: PMC4326483 DOI: 10.1186/s13071-015-0704-x] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2014] [Accepted: 01/28/2015] [Indexed: 11/27/2022] Open
Abstract
Background Fluralaner is a novel isoxazoline eliciting both acaricidal and insecticidal activity through potent blockage of GABA- and glutamate-gated chloride channels. The aim of the study was to investigate the susceptibility of juvenile stages of common tick species exposed to fluralaner through either contact (Rhipicephalus sanguineus) or contact and feeding routes (Ornithodoros moubata). Methods Fluralaner acaricidal activity through both contact and feeding exposure was measured in vitro using two separate testing protocols. Acaricidal contact activity against Rhipicephalus sanguineus life stages was assessed using three minute immersion in fluralaner concentrations between 50 and 0.05 μg/mL (larvae) or between 1000 and 0.2 μg/mL (nymphs and adults). Contact and feeding activity against Ornithodoros moubata nymphs was assessed using fluralaner concentrations between 1000 to 10−4 μg/mL (contact test) and 0.1 to 10−10 μg/mL (feeding test). Activity was assessed 48 hours after exposure and all tests included vehicle and untreated negative control groups. Results Fluralaner lethal concentrations (LC50, LC90/95) were defined as concentrations with either 50%, 90% or 95% killing effect in the tested sample population. After contact exposure of R. sanguineus life stages lethal concentrations were (μg/mL): larvae - LC50 0.7, LC90 2.4; nymphs - LC50 1.4, LC90 2.6; and adults - LC50 278, LC90 1973. After exposure of O. moubata nymphs to fluralaner lethal concentrations were (μg/mL): contact exposure - LC50 720, LC95 1133; and feeding exposure- LC50 0.00007, LC95 0.09. Conclusions Fluralaner demonstrates potent in vitro acaricidal activity against all life stages of the brown dog tick, R.sanguineus. The testing of fluralaner contact and feeding routes using O. moubata nymphs demonstrates a high acaricidal activity in both exposure routes.
Collapse
Affiliation(s)
- Heike Williams
- MSD Animal Health Innovation GmbH, Research Antiparasitics, Zur Propstei, 55270, Schwabenheim, Germany.
| | - Hartmut Zoller
- MSD Animal Health Innovation GmbH, Research Antiparasitics, Zur Propstei, 55270, Schwabenheim, Germany.
| | - Rainer K A Roepke
- MSD Animal Health Innovation GmbH, Research Antiparasitics, Zur Propstei, 55270, Schwabenheim, Germany.
| | - Eva Zschiesche
- MSD Animal Health Innovation GmbH, Research Antiparasitics, Zur Propstei, 55270, Schwabenheim, Germany.
| | - Anja R Heckeroth
- MSD Animal Health Innovation GmbH, Research Antiparasitics, Zur Propstei, 55270, Schwabenheim, Germany.
| |
Collapse
|
19
|
Taenzler J, Wengenmayer C, Williams H, Fourie J, Zschiesche E, Roepke RKA, Heckeroth AR. Onset of activity of fluralaner (BRAVECTO™) against Ctenocephalides felis on dogs. Parasit Vectors 2014; 7:567. [PMID: 25471474 PMCID: PMC4263043 DOI: 10.1186/s13071-014-0567-6] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2014] [Accepted: 11/24/2014] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Fluralaner (Bravecto™) is a novel systemic insecticide and acaricide that provides long persistent antiparasitic activity following a single administration at the minimum dose of 25 mg/kg body weight. METHODS Three negative controlled, randomized studies were conducted in dogs to evaluate the start to kill (1 study) and the speed of flea kill (2 studies) of fluralaner. All dogs were infested prior to treatment with unfed adult C. felis fleas. Dogs in the treated groups were administered once orally with fluralaner at a minimum dose of 25 mg/kg body weight, while dogs in the control groups were not treated. Separate control and treatment groups were paired at each time point of flea assessment. Flea counts were performed by combing dogs at either 0.5, 1, 2, or 4 hours after fluralaner treatment to measure the start to kill. To evaluate the speed of flea kill over 12 weeks, flea counts were performed by combing dogs at either 4, 8, 12, or 24 hours after fluralaner treatment and then at 4, 8, 12, or 24 hours after each flea re-infestations performed at 4, 8, and 12 weeks following treatment. RESULTS In the start to kill study, the fluralaner activity against fleas started already at 1 hour post-treatment (8% numerical efficacy). At 2 and 4 hours post-treatment, the flea reduction was significant with 36.7% and 88% efficacy, respectively. In the speed of kill studies, the efficacy against fleas after fluralaner treatment was 80.5% at 4 hours and remained ≥ 99.4% at 8, 12 and 24 hours. After flea re-infestations in weeks 4, 8 and 12, the efficacy at 4 hours was 96.8, 91.4, and 33.5%, respectively. Efficacy at 8, 12 and 24 hours after flea re-infestations was 98.0-100% for the 12 weeks of the study. Except for 4 hours after the 12-week flea re-infestation, flea reduction was significant for all time points after flea re-infestation. CONCLUSIONS Single oral fluralaner administration rapidly eliminates existing flea infestations and provides excellent protection against fleas over 12 weeks following treatment.
Collapse
Affiliation(s)
- Janina Taenzler
- MSD Animal Health Innovation GmbH, Zur Propstei, 55270, Schwabenheim, Germany.
| | | | - Heike Williams
- MSD Animal Health Innovation GmbH, Zur Propstei, 55270, Schwabenheim, Germany.
| | - Josephus Fourie
- ClinVet International, Uitsigweg, Bainsvlei, 9338, Bloemfontein, Free State, South Africa.
| | - Eva Zschiesche
- MSD Animal Health Innovation GmbH, Zur Propstei, 55270, Schwabenheim, Germany.
| | - Rainer K A Roepke
- MSD Animal Health Innovation GmbH, Zur Propstei, 55270, Schwabenheim, Germany.
| | - Anja R Heckeroth
- MSD Animal Health Innovation GmbH, Zur Propstei, 55270, Schwabenheim, Germany.
| |
Collapse
|
20
|
Wengenmayer C, Williams H, Zschiesche E, Moritz A, Langenstein J, Roepke RKA, Heckeroth AR. The speed of kill of fluralaner (Bravecto™) against Ixodes ricinus ticks on dogs. Parasit Vectors 2014; 7:525. [PMID: 25406442 PMCID: PMC4247686 DOI: 10.1186/s13071-014-0525-3] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2014] [Accepted: 11/05/2014] [Indexed: 12/26/2022] Open
Abstract
Background Pathogens that are transmitted by ticks to dogs, such as Anaplasma phagocytophilum, Babesia spp., Borrelia burgdorferi sensu latu, and Ehrlichia canis, are an increasing problem in the world. One method to prevent pathogen transmission to dogs is to kill the ticks before transmission occurs. Fluralaner (Bravecto™) is a novel isoxazoline insecticide and acaricide that provides long persistent antiparasitic activity following systemic administration. This study investigated the speed of kill of fluralaner against Ixodes ricinus ticks on dogs. Methods A total of 48 dogs were randomized to 8 groups of 6 dogs and each dog was infested with 50 female and 10 male I. ricinus ticks. Two days later (day 0), 4 groups received a single treatment of 25 mg fluralaner/kg body weight as Bravecto™ chewable tablets; the dogs in the other 4 groups were left untreated. Separate control and treatment groups were paired at each time point (4, 8, 12, or 24 hours after treatment) for assessment of tick-killing efficacy. At 4, 8, and 12 weeks after treatment, all dogs were re-infested with 50 female I. ricinus ticks and subsequently assessed for live or dead ticks at either 4, 8, 12, or 24 hours after re-infestation. Efficacy was calculated for each assessment time point by comparison of the treatment group with the respective control group. Results Tick-killing efficacy was 89.6% at 4 hours, 97.9% at 8 hours, and 100% at 12 and 24 hours after treatment. Eight hours after re-infestation, efficacy was 96.8%, 83.5%, and 45.8% at 4, 8, and 12 weeks after treatment, respectively. At least 98.1% tick-killing efficacy was demonstrated 12 and 24 hours after re-infestation over the entire 12 week study period. Conclusions Fluralaner kills ticks rapidly after treatment at 4 hours, and over its entire 12-week period of efficacy, it achieves an almost complete killing effect within 12 hours after tick infestation. The rapid tick-killing effect together with the long duration of efficacy enables fluralaner to aid in the prevention of tick borne diseases.
Collapse
Affiliation(s)
| | - Heike Williams
- MSD Animal Health Innovation GmbH, Zur Propstei, 55270, Schwabenheim, Germany.
| | - Eva Zschiesche
- MSD Animal Health Innovation GmbH, Zur Propstei, 55270, Schwabenheim, Germany.
| | - Andreas Moritz
- Department of Veterinary Clinical Sciences, Clinical Pathophysiology and Clinical Pathology, Justus-Liebig-University Giessen, Giessen, Germany.
| | - Judith Langenstein
- Department of Veterinary Clinical Sciences, Clinical Pathophysiology and Clinical Pathology, Justus-Liebig-University Giessen, Giessen, Germany.
| | - Rainer K A Roepke
- MSD Animal Health Innovation GmbH, Zur Propstei, 55270, Schwabenheim, Germany.
| | - Anja R Heckeroth
- MSD Animal Health Innovation GmbH, Zur Propstei, 55270, Schwabenheim, Germany.
| |
Collapse
|
21
|
Rohdich N, Roepke RKA, Zschiesche E. A randomized, blinded, controlled and multi-centered field study comparing the efficacy and safety of Bravecto (fluralaner) against Frontline (fipronil) in flea- and tick-infested dogs. Parasit Vectors 2014; 7:83. [PMID: 24593931 PMCID: PMC3975895 DOI: 10.1186/1756-3305-7-83] [Citation(s) in RCA: 94] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2013] [Accepted: 02/24/2014] [Indexed: 11/20/2022] Open
Abstract
Background Fluralaner, a new molecular entity of the isoxazoline class, has potent insecticidal and acaricidal activity and can be safely administered orally to dogs. Methods A randomized, investigator-blinded, multi-centered field study compared the flea- and tick-control efficacy for dogs over a 12-week period with either a single oral dose of Bravecto™ (fluralaner) formulated as a chewable tablet or with three sequential topical Frontline™ (fipronil) treatments. Individual dogs were the experimental unit for ticks and households were the experimental unit for fleas. A total of 108 tick-infested dogs were treated with Bravecto™ (fluralaner) and 54 tick-infested dogs were treated with Frontline™ (fipronil). Dogs in 115 flea-infested households received Bravecto™ (fluralaner) and dogs in 61 flea-infested households received Frontline™ (fipronil). Flea and tick counts were conducted on all dogs at weeks 2, 4, 8, and 12 following initial treatment and efficacy was calculated as the mean percent reduction in tick or flea count at each time point compared with the mean pretreatment initiation count for each treatment group. Additionally, the percentages of tick-free and flea-free households were determined. Results At weeks 2, 4, 8, and 12, Bravecto™ (fluralaner) flea-control efficacy in treated households was 99.2%, 99.8%, 99.8%, and 99.9% respectively, while Frontline™ (fipronil) efficacy was 94.1%, 93.0%, 96.0%, and 97.3%, respectively. Bravecto™ (fluralaner) tick-control efficacy on treated dogs at weeks 2, 4, 8, and 12 was 99.9%, 99.9%, 99.7%, and 100%, respectively, and Frontline™ (fipronil) tick efficacy was 97.6%, 93.8%, 100%, and 100%, respectively. Of dogs showing clinical flea allergy dermatitis (FAD) signs at the study start, 85.7% in the Bravecto™ (fluralaner)-treated group and 55.6% in the Frontline™ (fipronil)-treated group were evaluated at each time point as showing no clinical signs of FAD until study completion. Conclusions Bravecto™ (fluralaner) administered once orally to dogs in a chewable tablet was highly effective for 12 weeks against fleas and ticks on privately-owned dogs and was significantly non-inferior (ticks) and superior (fleas) in comparison with topical Frontline™ (fipronil) administered 3 times sequentially.
Collapse
Affiliation(s)
- Nadja Rohdich
- MSD Animal Health Innovation GmbH, Zur Propstei, 55270 Schwabenheim, Germany.
| | | | | |
Collapse
|
22
|
Taenzler J, Wengenmayer C, Williams H, Fourie J, Zschiesche E, Roepke R, Heckeroth AR. Onset of activity of fluralaner (BRAVECTO¿) against Ctenocephalides felis on dogs. Parasit Vectors 2014. [DOI: 10.1186/preaccept-1563099569137345] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
23
|
Wengenmayer C, Williams H, Zschiesche E, Moritz A, Langenstein J, Roepke R, Heckeroth AR. The speed of kill of fluralaner (Bravecto¿) against Ixodes ricinus ticks on dogs. Parasit Vectors 2014. [DOI: 10.1186/preaccept-2103142870137452] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
24
|
Rose M, Menge M, Bohland C, Zschiesche E, Wilhelm C, Kilp S, Metz W, Allan M, Röpke R, Nürnberger M. Pharmacokinetics of tildipirosin in porcine plasma, lung tissue, and bronchial fluid and effects of test conditions on in vitro activity against reference strains and field isolates of Actinobacillus pleuropneumoniae. J Vet Pharmacol Ther 2012; 36:140-53. [PMID: 22500881 DOI: 10.1111/j.1365-2885.2012.01397.x] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
The pharmacokinetics of tildipirosin (Zuprevo(®) 40 mg/mL solution for injection for pigs), a novel 16-membered-ring macrolide for the treatment for swine respiratory disease (SRD), was investigated in studies collecting blood plasma and postmortem samples of lung tissue and bronchial fluid (BF) from swine. In view of factors influencing the in vitro activity of macrolides, and for the interpretation of tildipirosin pharmacokinetics in relation to minimum inhibitory concentrations (MIC), additional experiments were conducted to study the effects of pH, carbon dioxide-enriched atmosphere, buffers, and serum on tildipirosin MICs for various reference strains and Actinobacillus (A.) pleuropneumoniae field isolates. After single intramuscular (i.m.) injection at 4 mg/kg body weight, maximum plasma concentration (Cmax) was 0.9 μg/mL observed within 23 min (Tmax ). Mean residence time from the time of dosing to the time of last measurable concentration (MRTlast) and terminal half-life (T1/2) both were about 4 days. A dose-response relationship with no significant sex effect is observed for area under the plasma concentration-time curve from time 0 to the last sampling time with a quantifiable drug concentration (AUClast) over the range of doses up to 6 mg/kg. However, linear dose proportionality could not be proven with statistical methods. The time-concentration profile of tildipirosin in BF and lung far exceeded that in blood plasma. In lung, tildipirosin concentrations reached 3.1 μg/g at 2 h, peaked at 4.3 μg/g at day 1, and slowly declined to 0.8 μg/g at day 17. In BF, tildipirosin levels were 14.3, 7.0, and 6.5 μg/g at days 5, 10, and 14. T1/2 in lung was ∼7 days. Tildipirosin is rapidly and extensively distributed to the respiratory tract followed by slow elimination. Culture media pH and carbon dioxide-enriched atmosphere (CO2 -EA) had a marked impact on in vitro activity of tildipirosin in reference strains of various rapidly growing aerobic and fastidious bacteria including Histophilus (H.) somni ATCC 700025 and A. pleuropneumoniae ATCC 27090. For A. pleuropneumoniae ATCC 27090 testing conditions without CO2 -EA resulted in reduced acidification of culture media pH and a reduction in the minimum inhibitory concentrations compared to standard in vitro test conditions by 2 log2 dilution steps (4-fold) from 8 to 2 μg/mL. Supplementary buffering of standard culture media resulted in a reduction in the A. pleuropneumoniae (n = 8) MIC range by 4 log2 dilution steps (16-fold) from 8-16 to 0.5-1 μg/mL. Incremental supplementation of culture media with 50% serum resulted in noticeable shifts to lower minimum or maximum MICs by at least 2 log2 dilution steps (≥4-fold) in all aerobic and fastidious reference strains tested except for Pasteurella (P.) multocida. The MIC of A. pleuropneumoniae ATCC 27090 decreased by 2-4 log2 dilution steps (4 to 16-fold) from 8 to 0.5-2 μg/mL when 50% serum was added to the standard assay. Considering a higher presence of serum and the rather neutral pH conditions maintained in vivo, it is suggested to take the influence of these factors on in vitro activity into account when interpreting tildipirosin MICs for A. pleuropneumoniae in relation to pharmacokinetics.
Collapse
Affiliation(s)
- M Rose
- Intervet Innovation GmbH, Zur Propstei, Schwabenheim, Germany
| | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Schmid K, Rohdich N, Zschiesche E, Kok DJ, Allan MJ. Efficacy, safety and palatability of a new broad-spectrum anthelmintic formulation in dogs. Vet Rec 2010; 167:647-51. [DOI: 10.1136/vr.c4661] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Affiliation(s)
- K. Schmid
- Intervet Innovation, Zur Propstei; 55270 Schwabenheim Germany
| | - N. Rohdich
- Intervet Innovation, Zur Propstei; 55270 Schwabenheim Germany
| | - E. Zschiesche
- Intervet Innovation, Zur Propstei; 55270 Schwabenheim Germany
| | - D. J. Kok
- ClinVet International; PO Box 11186, Universitas Bloemfontein 9321 South Africa
| | - M. J. Allan
- Intervet Innovation, Zur Propstei; 55270 Schwabenheim Germany
| |
Collapse
|
26
|
Rohdich N, Zschiesche E, Heckeroth A, Wilhelm C, Leendertse I, Thomas E. Treatment of septicaemia and severe bacterial infections in foals with a new cefquinome formulation: a field study. Dtsch Tierarztl Wochenschr 2009; 116:316-320. [PMID: 19813447] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
A multicentre field study was conducted in accordance with VICH Guideline on Good Clinical Practice (VICH 2000) to confirm the efficacy and safety of a new formulation of cefquinome for the treatment of naturally occurring severe bacterial infections and septicaemia in foals. Thirty-nine foals suffering from severe bacterial infections (such as pneumonia, gastro-enteritis, arthritis, omphalitis, or wound infections) or acute septicaemia were treated twice daily with the test product (1 mg cefquinome/kg body weight) intravenously for three days and then intramuscularly for three to 11 days. Investigators examined the foals daily and scored both systemic and local clinical signs to assess the response to treatment, treatment success and relapses. On the day of inclusion a blood sample was taken from each foal for IgG determination and blood culture. In case of abnormal clinical findings additional samples were taken for bacteriology. Treatment was successful in 87.2% of cases (34 of 39 foals) and no relapses were observed. The average duration of treatment was 7.5 days. At inclusion, bacterial culture was positive in 40.5% (15 out of 37) of the blood cultures. Escherichia coli, Clostridium perfringens and Staphylococcus spp. were the most common isolates and were all susceptible to cefquinome. E. coli predominated in swabs from umbilical and open wound infections, and in rectal swabs E. coli. There was no correlation between IgG at inclusion and study outcome or treatment duration. The test product was very well tolerated by all of the foals following intravenous and intramuscular injection. The cefquinome formulation tested was effective and safe in the treatment of severe bacterial infections and septicaemia in foals under field conditions.
Collapse
|
27
|
Wallmann J, Böttner A, Goossens L, Hafez HM, Hartmann K, Kaspar H, Kehrenberg C, Kietzmann M, Klarmann D, Klein G, Krabisch P, Kühn T, Luhofer G, Richter A, Schulz B, Schwarz S, Sigge C, Traeder W, Waldmann KH, Werckenthin C, Zschiesche E. Results of an interlaboratory test on antimicrobial susceptibility testing of bacteria from animals by broth microdilution. Int J Antimicrob Agents 2006; 27:482-90. [PMID: 16697559 DOI: 10.1016/j.ijantimicag.2005.12.011] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2005] [Accepted: 12/19/2005] [Indexed: 11/24/2022]
Abstract
A standard operating procedure for the determination of minimum inhibitory concentrations (MICs) of antimicrobial agents by the broth microdilution method was developed and evaluated for its fitness for use in an interlaboratory ring trial involving 46 routine diagnostic laboratories. All laboratories tested five strains (one reference strain and four field strains) against a total of 22 different antimicrobial agents. Gram-negative strains were tested against 16 different antimicrobial agents and Gram-positive strains against 14 different antimicrobial agents. Tests were performed once a week for three consecutive weeks. At least 80% of the results determined by 35 of the 46 participating laboratories were within the expected range (mode MIC+/-1 dilution step), with the 18 participating laboratories experienced in MIC determination showing a slightly higher mean percentage of accurate results (89.3% reproducible results) than the 28 non-experienced laboratories (86.7% reproducible results). The most accurate results were obtained for the Escherichia coli field strain, whilst the results for the Streptococcus uberis field strain showed the highest error rate. Among the 22 antimicrobial agents tested, the highest variabilities in the results (mean value for all antimicrobial agents 12.3%) were recorded for ceftiofur (27.8%), penicillin G (20.8%) and cefoperazone (20.6%).
Collapse
Affiliation(s)
- Jürgen Wallmann
- Federal Office of Consumer Protection and Food Safety (BVL), Diedersdorfer Weg 1, D-12277 Berlin, Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Wallmann J, Böttner A, Hafez HM, Kehrenberg C, Kietzmann M, Klarmann D, Klein G, Krabisch P, Kühn T, Luhofer G, Richter A, Schwarz S, Sigge C, Traeder W, Waldmann KH, Werckenthin C, Zschiesche E. [Results from a German interlaboratory test to establish the broth microdilution method for the determination of the minimum inhibitory concentration of bacteria from animals]. Berl Munch Tierarztl Wochenschr 2005; 118:205-13. [PMID: 15918484] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/02/2023]
Abstract
In accordance with NCCLS guideline M31-A2, the DVG working group "antimicrobial resistance" developed a standard operating procedure (SOP) for the determination of the minimal inhibitory concentration (MIC) of antimicrobial agents by broth microdilution. This SOP was evaluated for its fitness for use in a national interlaboratory test. A total of 32 participating laboratories tested five strains (including two internationally accepted reference strains and three field strains representing in total three different bacterial species) three times at a one week interval each, using uniform microtitre plates. In 31 of the 32 laboratories more than 80% of MIC determinations performed yielded values in the expected range. In total 94.0% of the results were reproducible, with a lesser deviation of 4.0% from the expected values for laboratories performing MIC determination as a matter of routine (46.9%), compared to 7.9% for laboratories without such routine (53.1%). Comparing the consistency of results on the basis of the tested strains, a higher reproducibility of the results was observed for reference strains (96.1%) than for field strains (92.6%). In particular results obtained for the Streptococcus uberis field strain were afflicted with a higher error ratio (98 deviations from the expected values). Among the tested antimicrobial agents, a higher variability of results was recorded only for gentamicin with 16.7% divergent MIC determinations (mean value 6.0%). The high reproducibility of the results confirmed by this interlaboratory study underlines the robustness of the developed SOP as well as broth microdilutions as the method of choice for MIC determina tion.
Collapse
Affiliation(s)
- Jürgen Wallmann
- Bundesamt für Verbraucherschutz und Lebensmittelsicherheit, Berlin.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Böttner A, Pirro F, Schmid P, Traeder W, Weiskopf S, Weiss H, Zschiesche E. [Guidelines for planning studies to determine the resistance of infectious agents of veterinary relevance]. Berl Munch Tierarztl Wochenschr 2000; 113:299-305. [PMID: 10994257] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/17/2023]
Abstract
This paper describes the most important criteria for the planning of statistically sound and representative studies on the prevalence of antimicrobial resistance among pathogenic bacteria from animals. The statistical design of the study is of particular importance and therefore described in some detail. The existing published data about antimicrobial resistance are mostly retrospective summaries of results and do not give a true picture of the resistance situation. The authors propose to conduct a pilot study initially because many basic elements for a sound study design are still not known. The systematic recording and assessment of the target variables including the necessary quality assurance are an important prerequisite. Moreover, potential cause variables can be further narrowed down and conclusively identified. To ensure the representativity of the cross-sectional study and avoid potential bias, it is important to achieve the highest possible response rate. This will form the basis of a scientifically sound resistance monitoring programme which should be the joint responsibility of regulatory authorities, industry and academia.
Collapse
Affiliation(s)
- A Böttner
- Bundesverband für Tiergesundheit e.V., Bonn
| | | | | | | | | | | | | |
Collapse
|